DICYNONE table. 500 mg. 20 table

DICYNONE table. 500 mg. 20 table
€ 39.00
Add to Cart
Etamsylate antihaemorrhagic is a synthetic product and vasoprotective acting in I-phase watt Hemostasis (interaction between the endothelium and platelets). Shortened bleeding time and decreased blood loss, enhancing platelet adhesion and restoring stability to the capillary wall.



DICYNONE table. 500 mg. 20 table
 

Ingredients:

Active substance: Etamsylate (etamsilat) 500 mg
 
Other ingredients: corn starch, microcrystalline cellulose, povidone, stearic acid, sodium dihydrogen citrate, anhydrous sodium sulfite
Features / Effects
 
Etamsylate antihaemorrhagic is a synthetic product and vasoprotective acting in I-phase watt Hemostasis (interaction between the endothelium and platelets). Shortened bleeding time and decreased blood loss, enhancing platelet adhesion and restoring stability to the capillary wall.
 
Etamsylate vasoconstrictor action will not affect fibrinolysis and alter plasma clotting factors.
 

Pharmacokinetics

 
When taken orally, etamsylate slowly absorbed from the gastrointestinal tract. After oral administration of 500 mg etamsylate, the maximum plasma concentration of 15 pg / ml was reached after 4 hours, but found no bioavailability data. The degree of protein binding is about 95%. The plasma half-life averaged 3.7 hours. During the first 24 hours is excreted in the urine about 72% of the dose as intact molecule.
 
Etamsylate crosses the placental barrier. Concentration in maternal blood and umbilical cord is approximately equal. It is not known whether etamsylate is excreted in human mlyako.Farmakokinetika in specific cases is not known whether etamsyIate pharmacokinetics in patients suffering from renal and / or hepatic function
 
Indications and usage
In surgery:
 
Prevention and treatment of preoperativno (before surgery) periperativno (during surgery) or postoperative (postoperative) capillary bleeding in all delicate operations and those involving intensive vascularised tissues: ENT (ear-nose-throat), gynecology, obstetrics, Urology, odontostomatologiya, ophthalmology, plastic and reconstructive surgery.
 

In Internal Medicine:

 
Prevention and treatment of capillary bleeding from any source or location: hematuria (blood in urine), hematemesis (vomiting blood), melena (blood in stool), epistaxis (nosebleeds), gingivoragiya (bleeding gums).
 
In gynecology:
 
Metrorrhagia (uterine bleeding), primary or associated with menorrhagia bearing intra-uterine devices (bleeding associated with spirals, etc.), in the absence of organic pathology.
 
Dosage:
 

Adults:

 
Preoperative: 1 tablet (500 mg), 1 hour before surgery.
 
Postoperatively, 1 tablet (500 mg), every 4-6 hours while. risk of bleeding
 
Internal Medicine: usually have to take 1 tablet 2-3 times daily (1000 to 1500 mg), with food, with water, the length of treatment depends on the results.
 
Gynecology, menorrhagia, metrorrhagia: to take 1 tablet 3 times daily (1500 mg), a meal with some water. Treatment lasts 10 days and begins 5 days before the expected menstrual cycle.
 

Children:

 
Due to the high concentration of the drug, Dicynone 500 is not suitable for children.
 
Restrictions on use
 Contraindications
 
Hypersensitivity to etamsylate and / or excipients. Acute porphyria, asthma, known hypersensitivity to sulfites.
 
Special warnings and precautions for use
 
Parenteral administration of Dicynone can cause a drop in blood pressure but have not reported data for such risk during oral prilozhenie.Ako Dicynone 500 is applied to reduce the heavy and / or prolonged menstrual bleeding and there is no improvement to look for and exclude possible pathological causes
 

Pregnancy and lactation

 
Pregnancy Category C: Animal studies have not shown a fetal risk but no controlled studies in pregnant women.
 
As a precaution, Dicynone 500 should not be administered during the first trimester of pregnancy, while during the II and II! quarter can only be applied if it is determined that the expected therapeutic benefit outweighs the potential risk to the fetus.
 
Due to lack of data on the passage of Dicynone 500 in milk, breastfeeding is not recommended during the implementation, if breastfeeding continued treatment should be stoppe
Adverse reactions
 
Rare: gastralgia (stomach ache), nausea, headache, skin rash. In most cases, these symptoms disappear spontaneously. If they persist, the dose should be reduced or treatment is terminated.
 
Dicynone 500 tablets contain an antioxidant sulfite that may cause allergic reactions, nausea and diarrhea in susceptible patients. Allergic reactions can lead to anaphylactic shock and cause life-threatening asthma attacks. The incidence is unknown, but is probably low. However, hypersensitivity to sulphite is observed more frequently in asthmatics versus non-asthmatics. In case of hypersensitivity reactions should be immediately discontinued use of Dicynone 500.
 

Interactions

 
Thiamine (vitamin B1) is inactivated by sulphite contained in Dicynone 500.
 
Effects on ability to drive and use machines
 
Dicynone 500 has no effect on ability to drive and use machine 

Overdose

 
Signs of overdose has been reported. In case of overdose, symptomatic treatment begins.
 

Specific comments:

 
Dicynone 500 should not be used after the expiry date shown on the pack (EXP :).
 
Do not store above 25 ° C.
 
Keep out of reach of children.
€ 39.00
Add to Cart
Close